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Is There a Role for the ob Gene Product
Leptin in Essential Hypertension?
Paolo M. Suter, Rudolf Locher, Erik Ha¨sler, and Wilhelm Vetter
In this study we wanted to evaluate the
relationship between the ob gene product leptin
and blood pressure, as well as plasma renin
activity and plasma aldosterone levels. We studied
139 subjects with a mean 6 SD age of 50 6 14
years and a body mass index of 26.5 6 5.3 kg/m2;
110 subjects had essential hypertension and 29
were healthy nonhypertensive controls. Blood
pressure was measured in resting conditions in the
morning and blood was drawn for the
determination of the plasma renin activity,
aldosterone, and leptin levels. The mean blood
pressure of the population was 155/97 mm Hg. The
relationship between these parameters was studied
by univariate regression analysis according to
gender and, whenever indicated, adjusted for age
and body mass. The mean 6 SEM plasma leptin
level in the whole population was 9.5 6 0.6 ng/mL
(range, 1.1–43.3). Subjects with stage I
hypertension had significantly higher plasma
leptin levels than normotensive subjects. Systolic
blood pressure correlated with the plasma leptin
levels and the leptin levels adjusted for body
weight in women (r 5 0.422, P < .01) and
nonhypertensive men (r 5 0.644, P 5 .03) only.
Plasma renin activity (r 5 0.329, P 5 .03) and
aldosterone levels (r 5 0.342, P 5 .026) correlated
with the leptin concentration. A significant
relationship between the peripheral expression of
the ob gene product leptin and systolic blood
pressure was found in women and nonhypertensive
men. In view of the multiple functions of leptin a
causal relationship is postulated and potential
mechanisms may involve modulatory effects of
leptin on neuropeptide Y, angiotensinogen gene
expression, the modulation of the autonomous
nervous system, or effects on the pituitary adrenal
axis. Direct relationships between both plasma
renin activity and aldosterone levels and leptin
support the potential importance of the
relationship between leptin and blood pressure.
Our observation may be of future importance for
the understanding of the link between the increase
in blood pressure and increasing body weight.
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The pathogenesis of essential hypertension isstill not fully elucidated. An increased bodyweight and obesity are often associated withincreased blood pressure and hypertension.
Nevertheless, the pathophysiologic mechanisms of es-
sential hypertension and the blood pressure rise in
obesity are not yet known and different mechanisms
have been suggested.1 Hormonal changes associated
with obesity, especially hyperinsulinemia, have been
suggested as an important pathophysiologic mecha-
nism for the development of hypertension in obese
subjects.1,2 Recently adipose tissue has been claimed
to be a hormone-producing tissue and several hor-
mones produced in the adipocytes have been identi-
fied, one of them being the ob gene product leptin.3
Leptin represents an adipocyte-derived plasma pro-
tein, which has been identified as the mutant gene
product in ob/ob mice.
Leptin (from the greek word leptos meaning thin)
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represents a 16-kDA protein secreted from the adipose
tissue cells. The circulating levels of leptin reflect the
white adipose tissue mass and, accordingly, there is a
rather good correlation between absolute body weight
or fat mass and circulating leptin levels. This adipose
tissue hormone may play a role in the regulation of
food intake and energy expenditure by its action on
central nervous system networks, including the mod-
ulation of the autonomous nervous system or interac-
tion with specific neurotransmitters.4,5 Although pres-
ently leptin’s major role seems to be in the regulation
of food intake and energy metabolism, recent evidence
suggests that this hormone may extend its effects and
functions well beyond these aspects of body weight
regulation to include other organ systems such as
kidney, lung, testis, prostate, bone marrow, as well as
the cardiovascular system.4,6–11 Due to these multiple
effects of leptin it is conceivable that this hormone
may directly or indirectly interfere with the regulation
of blood pressure and thus hypertension.
The discovery and description of the ob gene may
for the first time provide a molecular device to under-
stand the pathophysiologic basis of obesity and also
the associated metabolic disorders such as hyperten-
sion. In view of these new findings and concepts, in
this study we examined the possible associations be-
tween systolic and diastolic blood pressure, blood
pressure regulatory hormones (renin and aldoste-
rone), and serum leptin concentrations in normal con-
trols and hypertensive subjects.
SUBJECTS AND METHODS
One hundred thirty-nine subjects with a mean (6 SD)
age of 49.5 6 13.8 years and a mean (6 SD) body mass
index (BMI) of 26.5 6 5.3 kg/m2 participated in the
study. The mean body weight distribution of the pop-
ulation corresponds to 120% 6 2% of the Metropolitan
Life Insurance Ideal Body Weight. The gender distri-
bution of male to female (m/f) was equally distributed
for the whole population (75/64). Twenty-nine sub-
jects were healthy controls (m/f 5 13/16) recruited
from the hospital staff; 110 subjects were consecutive
admissions (m/f 5 62/48) to the Medical Policlinic at
the University Hospital of Zu¨rich. Seventy-seven
(56%) subjects were taking antihypertensive medica-
tion. The blood pressure, antihypertensive medica-
tion, and selected biochemical and anthropometric
characteristics of the study population are summa-
rized in Table 1. The admission diagnosis or one of the
major diagnoses of all subjects in the patient group
was an elevated blood pressure (ICD Code 401). Upon
arrival in the hospital the usual medical workup was
done and resting blood pressure was measured in a
sitting position after at least a 10-min rest using a
mercury sphygmomanometer; the heart rate was re-
corded at the same time. Height and weight were
measured and the BMI computed (BMI, weight [kg]
divided by height [meters] squared). Blood was
drawn in the morning after 10–12 h fasting for a
routine laboratory analysis (electrolytes, kidney and
TABLE 1. AGE, ANTHROPOMETRIC CHARACTERISTICS, BLOOD PRESSURE, LEPTIN LEVELS, PLASMA
RENIN ACTIVITY, AND ALDOSTERONE LEVELS IN THE STUDY POPULATION ACCORDING TO
ANTIHYPERTENSIVE MEDICATION
Parameter
All Patients
(n 5 139)
Without
Antihypertensive
Medication
(n 5 62)
With
Antihypertensive
Medication
(n 5 77) *P
Age (years)† 49 6 14 43 6 2 54 6 1 .000
Gender (m/f) 75/64 30/32 45/32 .20‡
Body weight (kg)† 75 6 1 68.8 6 2 78.7 6 1.8 .81
Height (m)† 1.68 6 0.1 1.68 6 0.1 1.67 6 0.1 .32
Body mass index (BMI; kg/m2) 26.5 6 0.5 24.4 6 0.6 28.3 6 0.6 .000
Systolic pressure (mm Hg) 156 6 3 142 6 4 167 6 3 .000
Diastolic pressure (mm Hg) 97 6 1 89 6 2 102 6 2 .000
Heart rate (beats/min) 73 6 1 71 6 2 75 6 2 .13
Serum leptin (ng/mL) 9.5 6 0.6 8.67 6 0.96 10.28 6 0.85 .21
Serum leptin/kg body weight (ng/mL/kg) 0.13 6 0.007 0.12 6 0.01 0.13 6 0.01 .47
Serum leptin/BMI (ng/mL) 0.34 6 0.02 0.34 6 0.03 0.36 6 0.03 .66
Plasma renin activity (mg/L/h)§ 1.96 6 0.4 1.06 6 0.74 2.34 6 0.47 .15
Plasma aldosterone (pmol/L)§ 206 6 16 205 6 31 207 6 19 .97
* P or the difference with or without medication.
† Mean 6 SD (all other, mean 6 SEM).
‡ by x2 statistics.
§ Only 105 subjects.
AJH–NOVEMBER 1998–VOL. 11, NO. 11, PART 11306 SUTER ET AL
liver function, and white and red blood cells) and
plasma was collected for the leptin assay. In a sub-
group of subjects (n 5 106) blood was drawn after the
subjects lay supine with an indwelling catheter for 30
min for the determination of plasma renin activity and
plasma aldosterone levels. The only exclusion criteria
were reduction dieting, overfeeding, or severe illness.
Leptin Radioimmunoassay (RIA) The plasma leptin
levels were determined by radioimmunoassay (RIA,
LINCO Research Inc., St. Charles, MO). In these kits
antibodies were raised against highly purified human
leptin and both the standard and tracer prepared with
human leptin. All samples were assayed in duplicate
and the reliability tested. The assay variability was
tested and was found to be in the range of 0.95%–1.2%.
Other Biochemical Determinations Fasting plasma
glucose was determined using standard laboratory
tests. Thyroid function was assessed by the measure-
ment of circulating thyroid stimulating hormone
(TSH) levels. Quantitative determination of plasma
renin activity (PRA) was done by the radioimmuno-
assay of generated angiotensin I (GammaCoat Plasma
Renin Activity 125I RIA Kit, Incstar Corporation, Still-
water, MN) and plasma aldosterone levels were de-
termined by a radioimmunoassay.12
Statistical Methods The normality of the data was
confirmed by the Shapiro-Wilk W test. The potential
relations between the variables of interest were tested
by univariate regression analysis. All statistical tests
are two-tailed and a P , .05 was regarded as statisti-
cally significant. All values are expressed as mean 6
SEM, unless otherwise stated. Because some parame-
ters of interest were not normally distributed, selected
analyses were done based upon a natural log trans-
formation of the measured values. The statistical anal-
ysis were done with the JMP 2.05 Program (SAS Insti-
tute Inc., Cary, NC) and the StatView Program
(Abacus Concepts, Berkeley, CA). Many factors may
affect plasma leptin levels; however, body weight
seems to be of major importance. Because the plasma
leptin levels reflect mainly the white adipose tissue
mass per body weight, the measured plasma leptin
levels were adjusted for absolute body weight (kg) or
BMI whenever indicated. Because women show
higher leptin levels for a certain adipose tissue mass or
body weight, selected analyses have been made sepa-
rately by gender.13
RESULTS
The ob gene product was expressed in all subjects, and
the mean (6 SEM) plasma leptin level in the popula-
tion was 9.5 6 0.6 ng/mL (range, 1.1 to 43.3). Women
had significantly higher leptin levels than men (12.0 6
0.95 ng/mL v 6.65 6 0.78 ng/mL, P , .001); in both
gender groups as well as the whole population the
plasma leptin values were normally distributed. The
gender difference in plasma leptin levels was found in
subjects with a body mass index (BMI, kg/m2) # 25
kg/m2 and $ 25 kg/m2. The relationship between
body weight and plasma leptin levels according to
gender in the population is shown in Figure 1.
The mean systolic and diastolic blood pressures of
the whole population were 155 6 3 mm Hg and 97 6
1 mm Hg, respectively. The systolic blood pressure
correlated with the BMI in the subjects without anti-
hypertensive medication (r 5 0.514, P , .0001; ad-
justed for age); the corresponding values for the dia-
stolic blood pressure were r 5 0.462 and P , .001,
respectively. Sixty-seven percent of the subjects
showed a systolic blood pressure $ 140 mm Hg, and
66% of the subjects had a diastolic pressure $ 90 mm
FIGURE 1. Relationship between
body weight (kg) and plasma leptin
levels (ng/mL) in men and women.
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Hg. Plasma leptin levels in subjects less than or greater
than the latter systolic cutoff were 8.3 6 1.2/10.5 6 0.8
ng/mL (P 5 .1 for the difference). The corresponding
values for the diastolic cutoff were 8.1 6 1.2/10.7 6 0.8
ng/mL (P 5 .07), respectively. Plasma leptin levels 6
SEM in the entire population according to systolic and
diastolic blood pressure status using the U.S.-Joint
National Committee criteria14 are summarized in Ta-
ble 2 (ANOVA for nonsignificant trend). The male/
female ratio in the different blood pressure groups
was identical in all stages of hypertension (x2, ns).
Plasma leptin levels were significantly higher in
stage I hypertensives than in subjects with normal
blood pressure (10.1 6 0.98 ng/mL v 6.7 6 1.2 ng/mL,
P 5 .03); adjusting the leptin levels for body weight
(kg) or body mass index (kg/m2) led to a loss of the
statistical significance of the difference; however, a
lower plasma leptin concentration in the nonhyperten-
sive subjects was still evident (0.13 6 0.01 ng/mL v
0.14 6 0.01 ng/mL).
There was no correlation between leptin and the
systolic (r 5 0.158, P 5 .07) and diastolic (r 5 0.165,
P 5 .06) blood pressure in the whole population (ie,
including subjects taking antihypertensive medica-
tion). The univariate correlation coefficient (r) between
plasma leptin levels and systolic and diastolic blood
pressure for the population, as well as in different
subgroups of the population according to gender and
hypertension status, is summarized in Table 3. The
relationship was found to be significant in women and
nonhypertensive men only. There was no difference in
leptin levels in subjects according to the presence of
antihypertensive therapy.
The plasma renin activity (PRA) did not correlate
with plasma leptin levels in the whole population (r 5
0.054, P 5 .53). In the whole population plasma aldo-
sterone levels correlated positively with plasma leptin
levels (r 5 0.196, P 5 .04). Limiting the analysis to
subjects without antihypertensive medication or with-
out any medication influencing the renin-angiotensin-
aldosterone system (n 5 42) showed a positive rela-
tion for the PRA (r 5 0.329, P 5 .03) as well as
aldosterone levels (r 5 0.342, P 5 .026) with increasing
plasma leptin levels (Fig. 2).
Heart rate correlated significantly with plasma lep-
tin levels in the whole population (r 5 0.224, P 5 .01)
independently of gender. In subjects without any an-
tihypertensive medication this relationship was r 5
0.372 (P 5 .008). No relationship was found between
age and plasma leptin levels.
DISCUSSION
Our data show a positive relationship between sys-
tolic blood pressure and plasma leptin concentration.
This relationship was found to be significant in
women and nonhypertensive men only.
Several lines of evidence based on our descriptive
data suggest a potential role of the ob gene product
leptin in the regulation of blood pressure or in the
pathogenesis of essential hypertension. First, leptin
levels (adjusted for adipose tissue mass or body mass)
TABLE 2. SERUM LEPTIN LEVELS 6 SEM IN THE
WHOLE POPULATION ACCORDING TO BLOOD
PRESSURE STATUS USING THE U.S.-JOINT
NATIONAL COMMITTEE CLASSIFICATION
CRITERIA14
n
Serum Leptin
(ng/mL)
Serum Leptin
(ng/mL/[kg
body weight])
Systolic blood pressure
Normal 23 6.7 6 1.6 0.11 6 0.02
High normal 14 9.7 6 2.0 0.12 6 0.02
Stage I 33 10.1 6 1.3 0.14 6 0.01
Stage II 25 11.7 6 1.5 0.13 6 0.02
Stage III 23 9.6 6 1.6 0.13 6 0.02
Stage IV 8 11.5 6 2.6 0.17 6 0.03
Diastolic blood pressure
Normal 31 7.9 6 1.4 0.11 6 0.01
High normal 4 5.9 6 3.8 0.11 6 0.04
Stage I 33 10.1 6 1.3 0.13 6 0.01
Stage II 24 10.9 6 1.5 0.14 6 0.02
Stage III 24 10.5 6 1.6 0.13 6 0.02
Stage IV 10 11.6 6 2.43 0.15 6 0.03
TABLE 3. UNIVARIATE CORRELATIONS (r,
ADJUSTED FOR AGE) BETWEEN TOTAL PLASMA
LEPTIN, ADJUSTED FOR BODY WEIGHT, AND BP
(SYSTOLIC/DIASTOLIC) FOR THE WHOLE
POPULATION AND SUBGROUPS, ACCORDING TO
GENDER AND BP MEDICATION
Group/Subgroup
r With
Total Leptin
r With
Leptin/kg
Body Weight*
Whole population 0.115/0.106 0.100/0.050
Without medication† 0.322‡/0.200 0.264§/0.122
Hypertensives 0.056/0.060 0.078/0.018
Normotensive controls 0.329#/0.220 0.149/0.203
Men
All 0.089/0.119 0.000/0.014
Without medication 0.230§/0.219 0.210§/0.146
Hypertensives 20.144/20.209 20.109/20.165
Normotensive controls 0.644§/0.291 0.631§/0.258
Women
All 0.317‡/0.330‡ 0.361**/0.343‡
Without medication 0.422‡/0.254 0.401§/0.224
Hypertensives 0.150/0.300# 0.233/0.348#
Normotensive controls 0.116/0.177 0.127/0.240
* Plasma leptin levels divided by body weight (see Subjects and Methods
section); † The group without medication includes healthy controls and
hypertensive patients without medication; ‡ P , .01; § P , .05; # .05 ,
P , .09; ** P , .001.
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correlated with systolic blood pressure in women and
in nonhypertensive men. The relationship was not
significant for diastolic blood pressure. This relation-
ship was independent of age and body weight. Sec-
ond, serum leptin levels correlated with plasma renin
activity (PRA) and aldosterone plasma levels (Fig. 2).
Third, there was a close relationship between heart
frequency and plasma leptin levels, which is in agree-
ment with modulatory effects of leptin on the sympa-
thetic nervous system. This constellation of findings in
our population suggests a role for the ob gene product
in blood pressure regulation. The described relation-
ships were statistically not very strong, which may be
due to the heterogeneity of our study population or
the possibility that leptin only has a minor role in the
pathogenesis of hypertension.
Our findings are in agreement with a recent study of
the metabolic significance of leptin in humans, where
a relationship between elevated systolic and diastolic
blood pressure has been described in men.15 Interest-
ingly, in this study no relationship was found for
women. These authors suggested that the lack of a
relationship between blood pressure and leptin levels
in women is in agreement with the findings that leptin
is associated with insulin resistance only in men and
that insulin resistance is associated with an elevated
blood pressure.
There are several lines of evidence that may support
our hypothesis that leptin may play a role in blood
pressure regulation. An increased body weight and
obesity are associated with increased blood pressure.
Serum insulin levels correlate with serum leptin lev-
els16 and it may be hypothesized that these two hor-
mones may interact and modulate the effects of each
other and contribute to a common mechanism leading
to hypertension.2,17 Because we did not measure fast-
ing insulin levels in our patients no statement regard-
ing the interaction between the two hormones of in-
terest can be made.
The importance of the classical renin-angiotensin
system (RAS) in the regulation of blood pressure is
well known and established.18 Several lines of evi-
dence suggest that the angiotensinogen (AGT) gene is
expressed in different tissues, including the adipose
tissue.19,20 Accordingly, adipose tissue may contribute
to the regulation of blood pressure, as AGT represents
the substrate from which the hypertensive hormone
angiotensin II is formed and adipocytes have been
shown to form angiotensin-I and angiotensin-II.19,21,22
It has been reported that in hypertensive animals
the AGT gene shows a higher expression in adipose
tissue than in normotensive controls, independent
of body weight. Further it was shown that the AGT
is elevated in adipose tissue from obese ob/ob and
db/db mice.23 The AGT expression in adipose tissue
is regulated by different factors and was shown to
decrease during fasting and was restored by refeed-
ing, situations that are parallel to a decrease and
increase of the blood pressure, respectively. Insulin
has been shown to increase AGT mRNA content in
adipocytes.23 Recently it has been suggested that the
ob gene product leptin may contribute to the up-
regulation of this gene in adipocytes and thus may
eventually contribute to the pathogenesis of hyper-
tension.21–25 These findings may suggest that the
relationship between blood pressure and leptin lev-
els may be of pathophysiologic importance. How-
ever, as summarized in Figure 3, the role of leptin
may be of only secondary, indirect importance by
modulating other endocrine factors of blood pres-
sure regulation such as stimulation of the produc-
tion of angiotensinogen in adipose tissue.
An increase in body weight or obesity has been
found to result in an activation of the sympathetic
nervous system, which is also reflected in higher epi-
nephrine and norepinephrine plasma levels in obese
subjects.2,26 Leptin interacts with specific receptors in
the hypothalamus and has been reported to decrease
FIGURE 2. Relationship between
plasma leptin levels and plasma re-
nin activity and plasma aldosterone
levels.
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the levels of neuropeptide Y (NPY).5,9,27,28 It has been
hypothesized that the suppression of NPY by leptin
leads to an activation of the sympathetic nervous sys-
tem.15 The latter hypothesis seems attractive but re-
mains to be proved. NPY has many different central
and peripheral cardiovascular effects that may di-
rectly or indirectly affect blood pressure.29 Hypercor-
tisolism may also contribute to the pathogenesis of
higher blood pressure, as hyperleptinemia may also
lead to an increase in basal plasma ACTH and cor-
ticosterone levels in certain experimental condi-
tions.30 In obese subjects, therefore, two mecha-
nisms may lead to increased blood pressure and
both may be related to increased leptin levels in
obese subjects. The increased activity of the sympa-
thetic nervous system in obesity and increased an-
giotensin I and II production at the level of the
adipocyte may lead to increased vasoconstrictory
stimulus and thus hypertension.
Further, leptin may be of crucial importance in the
regulation of fuel homeostasis,16 and the proportion of
oxidation of the different energy substrates may affect
the regulation of vascular tone and thus affect blood
pressure. Another possible mechanism for the poten-
tial effects of leptin on the regulation of blood pressure
may be through the effects on neural networks, which
may interfere with regulatory systems of blood pres-
sure in the central nervous system. Many effects of the
ob gene product seem to be mediated by the modula-
tion of the sympathetic nervous system or by modu-
lation of the central nervous system output.27 In an
animal model using Sprague-Dawley rats the chronic
infusion of leptin led to a reversible increase in arterial
pressure.31 The potential mechanisms and interrela-
tions are summarized in Figure 3.
Our data suggest a relationship between the periph-
eral expression of the ob gene product leptin and
systolic blood pressure in women and nonhyperten-
sive men. Whether this association is independent
from other factors (especially other hormones, such as
insulin) is unknown and our data do not permit us to
formulate defined mechanisms for the leptin-blood
pressure interaction. It is not possible to give a final
answer to the question formulated in the title of this
paper. In view of the low-level correlations in this
study and the known relative importance of other
hormones and mediators in the regulation of blood
pressure, the most likely answer would be “not
much.” Nevertheless, our observation may be of fu-
ture importance for the understanding of the link be-
tween the increase in blood pressure and increasing
body weight.
FIGURE 3. A hypothetical model of the role of the ob gene product leptin in blood pressure regulation.
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